The estimated Net Worth of Anthony Caracciolo is at least $10.8 million dollars as of 22 November 2005. Anthony Caracciolo owns over 130,890 units of Gilead Sciences stock worth over $10,594,237 and over the last 21 years Anthony sold GILD stock worth over $214,429.
Anthony has made over 5 trades of the Gilead Sciences stock since 2003, according to the Form 4 filled with the SEC. Most recently Anthony exercised 130,890 units of GILD stock worth $2,115,182 on 22 November 2005.
The largest trade Anthony's ever made was exercising 130,890 units of Gilead Sciences stock on 22 November 2005 worth over $2,115,182. On average, Anthony trades about 22,940 units every 60 days since 2003. As of 22 November 2005 Anthony still owns at least 130,890 units of Gilead Sciences stock.
You can see the complete history of Anthony Caracciolo stock trades at the bottom of the page.
Anthony's mailing address filed with the SEC is 650 CLIFFSIDE DRIVE, , SAN DIMAS, CA, 91773.
Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger et John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences executives and other stock owners filed with the SEC include: